Spero Therapeutics Inc
SPRO2.420USD
+0.120+5.22%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
136.27MMarket Cap
LossP/E TTM
More Details of Spero Therapeutics Inc Company
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Spero Therapeutics Inc Info
Ticker SymbolSPRO
Company nameSpero Therapeutics Inc
IPO dateNov 02, 2017
CEORajavelu (Esther)
Number of employees32
Security typeOrdinary Share
Fiscal year-endNov 02
Address675 Massachusetts Ave Ste 14
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02139-3309
Phone18572421600
Websitehttps://sperotherapeutics.com/
Ticker SymbolSPRO
IPO dateNov 02, 2017
CEORajavelu (Esther)
Company Executives of Spero Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-6572.00%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
188.41K
-40270.00%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
145.31K
-1695.00%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
91.45K
+20000.00%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
75.00K
+20000.00%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
75.00K
+20000.00%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
75.00K
+20000.00%
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-6572.00%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
188.41K
-40270.00%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
145.31K
-1695.00%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
91.45K
+20000.00%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
75.00K
+20000.00%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
75.00K
+20000.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
By BusinessUSD
Name
Revenue
Proportion
Collaboration Revenue Related Party
3.05M
56.01%
Grant Revenue
2.39M
43.99%
Collaboration Revenue
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
5.44M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Collaboration Revenue Related Party
3.05M
56.01%
Grant Revenue
2.39M
43.99%
Collaboration Revenue
0.00
0.00%
Shareholding Stats
Updated: Sat, Feb 7
Updated: Sat, Feb 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
GSK plc
16.31%
Pfizer Inc
4.19%
The Vanguard Group, Inc.
3.70%
Anson Funds Management LP.
2.85%
Renaissance Technologies LLC
2.58%
Other
70.37%
Shareholders
Shareholders
Proportion
GSK plc
16.31%
Pfizer Inc
4.19%
The Vanguard Group, Inc.
3.70%
Anson Funds Management LP.
2.85%
Renaissance Technologies LLC
2.58%
Other
70.37%
Shareholder Types
Shareholders
Proportion
Corporation
20.51%
Hedge Fund
6.27%
Investment Advisor
5.88%
Individual Investor
2.87%
Investment Advisor/Hedge Fund
2.52%
Venture Capital
1.64%
Research Firm
0.20%
Bank and Trust
0.02%
Other
60.09%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
108
9.24M
16.40%
-3.05M
2025Q3
106
9.05M
16.08%
-5.89M
2025Q2
114
26.06M
46.61%
-2.84M
2025Q1
116
27.38M
49.07%
-1.56M
2024Q4
125
27.51M
50.50%
+2.91M
2024Q3
143
24.19M
44.62%
-8.19M
2024Q2
160
25.74M
47.53%
-7.31M
2024Q1
203
25.36M
47.08%
-8.60M
2023Q4
209
24.88M
47.35%
-1.62M
2023Q3
223
24.62M
47.01%
-2.06M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
GSK plc
9.19M
16.31%
--
--
Mar 27, 2025
Pfizer Inc
2.36M
4.19%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
1.99M
3.53%
+39.47K
+2.02%
Sep 30, 2025
Anson Funds Management LP.
1.60M
2.85%
-11.90K
-0.74%
Sep 30, 2025
Renaissance Technologies LLC
1.45M
2.58%
+620.60K
+74.58%
Sep 30, 2025
Alphabet, Inc.
889.98K
1.58%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
527.48K
0.94%
+16.78K
+3.29%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
433.55K
0.77%
--
--
Sep 30, 2025
Rajavelu (Esther)
188.41K
0.33%
-40.27K
-17.61%
Nov 07, 2025
Mahadevia (Ankit)
364.22K
0.65%
-6.57K
-1.77%
Aug 28, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.63%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.63%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
